Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab

keskiviikko 19. helmikuuta 2014 päivittänyt: AbbVie (prior sponsor, Abbott)

[E S] A Greek, Post-marketing, Observational Study of the quAlity of Life in Patients With Psoriasis Treated With Adalimumab - GOAL Study

Primary objective

  • To evaluate the quality of life of Adalimumab treated patients over a period of 12 months

Secondary objectives

  • To evaluate the long-term efficacy of Adalimumab in patients with moderate to severe chronic plaque psoriasis as prescribed by the dermatologists in day-to-day clinical practice and in accordance with the terms of the European marketing authorization.
  • To evaluate changes in patients quality of life according to treatment response over a 12-month period
  • To observe and assess the long term use and safety of Adalimumab as prescribed by the dermatologist in a normal clinical setting and in accordance with the terms of the European marketing authorization.

Tutkimuksen yleiskatsaus

Tila

Valmis

Ehdot

Yksityiskohtainen kuvaus

The aim of this post-marketing observational study in adult patients with moderate to severe chronic plaque psoriasis is to obtain further data on patient's Quality of Life and assess the impact of Adalimumab treatment on patient's quality of life in conditions of day-to-day clinical practice in Greece. This study will further assess the relationship between clinical outcomes and patient-reported outcomes. As this is an observational study, Abbott will not provide the study drug. Humira will be prescribed according to the routine medical practice. The participating physicians are free to determine the appropriate therapy for each patient and make treatment choices as deemed clinically necessary.

The Dermatology Life Quality Index (DLQI) will be used to assess patient quality of life. The Dermatology Life Quality Index (DLQI) total scores range from 0 to 30, with 0 corresponding to the best quality of life and 30 to the worst. The Dermatology Life Quality Index (DLQI) has well-established reliability and validity as determined in several studies. Moreover, it is frequently used in clinical trials of psoriasis.

The physician's global assessment of disease severity (PGA) will be used to measure patients' disease status at the time of assessment. It is a 6-point scale measuring the degree of overall psoriatic lesion severity, and scores range from 0 (clear) to 5 (very severe).

Complementary, European Quality of Life-5 Dimensions health questionnaire (EQ5D) will be used as a measure of health outcome. This is applicable to a wide range of health conditions and treatments and it provides a simple descriptive profile and a single index value for health status. Health economic data will be collected by using European Quality of Life-5 Dimensions health questionnaire (EQ5D) questionnaire and data regarding patients hospitalisation due to psoriasis. Hospitalisation data will be collected 6 months before the period and throughout the observation period.

Moreover, this study will observe the current medical practice in prescribing Adalimumab in Greece and more detailed data on prescription behavior will be collected. Guidelines have been developed in order to ensure that the new class of therapy (biologic agents) is introduced in a systematic and planned way to achieve the greatest possible benefit to people with psoriasis and to facilitate safe and effective prescribing. However, many issues are not fully addressed, such as recommendation regarding the amount of time for wash out of previous antipsoriatic drugs and combination therapies. Such issues remain at the discretion of the healthcare professional. Since this is an observational study the patient will be treated in accordance with the physician's usual and customary medical practice. Thus, the following information regarding the use of Adalimumab will be collected

  • the previous systemic treatment history will be recorded including previous biological therapies that patient received, if any,
  • wash out periods prior to initiating Adalimumab therapy, if any
  • reasons for stopping previous treatment,
  • combination of Adalimumab with other topical or systemic antipsoriatic agents, if applicable

Furthermore, demographic data of patients suffering from psoriasis in Greece will be collected (age, gender, ethnicity) and disease data such as duration of the disease, involvement of nails or joints, geographic distribution of the disease in Greece will be collected.

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Todellinen)

500

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

  • Kreikka
      • Agrinio, Kreikka, 301 00
        • Site Reference ID/Investigator# 43746
      • Amaliada, Kreikka
        • Site Reference ID/Investigator# 30197
      • Argos, Kreikka, 21200
        • Site Reference ID/Investigator# 30039
      • Argyroupoli, Kreikka
        • Site Reference ID/Investigator# 29903
      • Athens, Kreikka, 10673
        • Site Reference ID/Investigator# 29819
      • Athens, Kreikka, 11526
        • Site Reference ID/Investigator# 29949
      • Athens, Kreikka, 16121
        • Site Reference ID/Investigator# 30804
      • Athens, Kreikka, 16121
        • Site Reference ID/Investigator# 30806
      • Athens, Kreikka, 16121
        • Site Reference ID/Investigator# 38324
      • Athens, Kreikka
        • Site Reference ID/Investigator# 22385
      • Athens, Kreikka
        • Site Reference ID/Investigator# 29826
      • Athens, Kreikka
        • Site Reference ID/Investigator# 29966
      • Athens, Kreikka
        • Site Reference ID/Investigator# 29991
      • Athens, Kreikka
        • Site Reference ID/Investigator# 30106
      • Athens, Kreikka
        • Site Reference ID/Investigator# 30107
      • Athens, Kreikka
        • Site Reference ID/Investigator# 30181
      • Athens, Kreikka
        • Site Reference ID/Investigator# 30470
      • Chania, Crete, Kreikka, 73136
        • Site Reference ID/Investigator# 30086
      • Chania, Crete, Kreikka
        • Site Reference ID/Investigator# 43744
      • Crete, Kreikka, 71409
        • Site Reference ID/Investigator# 30794
      • Crete, Kreikka
        • Site Reference ID/Investigator# 29937
      • Crete, Kreikka
        • Site Reference ID/Investigator# 29959
      • Crete, Kreikka
        • Site Reference ID/Investigator# 29969
      • Drama, Kreikka
        • Site Reference ID/Investigator# 38334
      • Florina, Kreikka, 53100
        • Site Reference ID/Investigator# 30801
      • Giannitsa, Kreikka, 58100
        • Site Reference ID/Investigator# 29919
      • Giannitsa, Kreikka
        • Site Reference ID/Investigator# 30202
      • Glyfada, Kreikka, 16675
        • Site Reference ID/Investigator# 29970
      • Glyfada, Kreikka, 16675
        • Site Reference ID/Investigator# 30013
      • Glyfada, Kreikka
        • Site Reference ID/Investigator# 29823
      • Halandri, Kreikka
        • Site Reference ID/Investigator# 30193
      • Kalamaria, Kreikka
        • Site Reference ID/Investigator# 30083
      • Kallithea, Kreikka, 17672
        • Site Reference ID/Investigator# 30143
      • Katerini, Kreikka, 60100
        • Site Reference ID/Investigator# 47262
      • Keratsini, Kreikka
        • Site Reference ID/Investigator# 38329
      • Kolonaki, Kreikka, 10675
        • Site Reference ID/Investigator# 30108
      • Kosmos, Kreikka
        • Site Reference ID/Investigator# 30009
      • Larissa, Kreikka, 41100
        • Site Reference ID/Investigator# 38323
      • Larissa, Kreikka
        • Site Reference ID/Investigator# 38340
      • Livadeia, Kreikka
        • Site Reference ID/Investigator# 29822
      • Makri, Kreikka
        • Site Reference ID/Investigator# 30180
      • Mitilini, Kreikka
        • Site Reference ID/Investigator# 29834
      • Mitilini, Kreikka
        • Site Reference ID/Investigator# 30469
      • N.Heraklion, Kreikka
        • Site Reference ID/Investigator# 38326
      • Neapoli, Kreikka
        • Site Reference ID/Investigator# 30032
      • Pagkrati, Kreikka, 11634
        • Site Reference ID/Investigator# 30104
      • Patras, Kreikka
        • Site Reference ID/Investigator# 29817
      • Peiraius, Kreikka
        • Site Reference ID/Investigator# 29967
      • Peristeri, Kreikka
        • Site Reference ID/Investigator# 38327
      • Petralona, Kreikka
        • Site Reference ID/Investigator# 30109
      • Smyrni, Kreikka
        • Site Reference ID/Investigator# 29824
      • Thessaloniki, Kreikka, 54643
        • Site Reference ID/Investigator# 38325
      • Thessaloniki, Kreikka, 564 29
        • Site Reference ID/Investigator# 30769
      • Thessaloniki, Kreikka
        • Site Reference ID/Investigator# 30170
      • Thessaloniki, Kreikka
        • Site Reference ID/Investigator# 38331
      • Thessaloniki, Kreikka
        • Site Reference ID/Investigator# 38332
      • Thessaloniki, Kreikka
        • Site Reference ID/Investigator# 38333
      • Thessaloniki, Kreikka
        • Site Reference ID/Investigator# 38335
      • Thessaloniki, Kreikka
        • Site Reference ID/Investigator# 38337
      • Vari, Kreikka, 16672
        • Site Reference ID/Investigator# 30203
      • Volos, Kreikka
        • Site Reference ID/Investigator# 29921

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

Patients treated with Adalimumab according to routine medical practice from hospital and private physicians.

Kuvaus

Inclusion Criteria:

  • Patients with moderate to severe chronic plaque psoriasis who are newly prescribed Humira (adalimumab) therapy (have never been treated with adalimumab before) and for whom the treating physician has made the decision that they are eligible for treatment with adalimumab in accordance with the terms of the local marketing authorization
  • Patients with moderate to severe chronic plaque psoriasis for whom Adalimumab is indicated and has been prescribed according to the current approved local SPC as long as the first administration of adalimumab is not older than two months and they have not had dose interruptions since the initiation of adalimumab, and the Investigator can provide all the needed source documentation including a completed DLQI questionnaire at the start of Adalimumab treatment.
  • Patient age ≥ 18
  • Patient is willing to consent to data being collected and provided to Abbott

Exclusion Criteria:

  • Patients who meet contraindications as outlined in the latest version of the local approved SPC
  • Patients who participate in another clinical/observational study
  • Patients who are not willing to sign an Informed Consent Form

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

Kohortit ja interventiot

Ryhmä/Kohortti
Patients with psoriasis
All eligible patients with psoriasis treated with Adalimumab

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Mean Change of Dermatology Life Quality Index (DLQI) Scores
Aikaikkuna: 12-month period, (Month 0, Month 1, Month 4, Month 8, Month 12)
DLQI (Dermatology Life Quality Index) assesses symptoms and impacts of dermatologic diseases on quality of life. DLQI scores range from 0 to 30, with a higher score indicating a more impaired quality of life.
12-month period, (Month 0, Month 1, Month 4, Month 8, Month 12)

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Percentage of Patients Who Experienced an Improvement in Disease Severity as Determined by the Physician's Global Assessment of Disease Severity (PGA) Scores
Aikaikkuna: 12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)
The Physician's Global Assessment of disease severity (PGA) was used to measure participants' disease status at the time of assessment. This tool is a horizontal visual analogue 6-point scale measuring the degree of overall psoriatic lesion severity, and scores range from 0 (clear) to 5 (very severe). The percentage of patients who showed an improvement from baseline in their PGA scores was recorded.
12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)
Mean Change in the Dermatology Life Quality Index (DLQI) Score by Physician's Global Assessment of Disease Severity (PGA) Response Groups and by Geographical Region
Aikaikkuna: 12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)
The average change in the Dermatology Life Quality Index (DLQI) score during the 12-month study was analyzed by the Physician's Global Assessment of disease severity (PGA) response and also by geographical location of study participants. DLQI scores range from 0 to 30, with a higher score indicating a more impaired quality of life. . In this table, a higher number means a greater improvement in the participants' quality of life.
12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)
Percentage of Patients Reporting "No Problem" on the European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D)
Aikaikkuna: 12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)

EQ-5D (European Quality of Life - 5 Dimensions Questionnaire) is a standardized instrument for use as a measure of health outcome.

It has two components:

  1. the EQ-5D descriptive system (i.e., the EQ-5D Index Score, comprised of five items), and
  2. the EQ-5D VAS. The EQ-5D Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Patients reported either "problem" or "no problem" with each of the five dimensions of health. The EQ-5D VAS is a 20-cm scale with endpoints labeled "best imaginable health" and "worst imaginable health" anchored at 100 and 0, respectively.
12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)
Mean Change From Baseline of European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Visual Analogue Scale (VAS) Scores
Aikaikkuna: 12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)

EQ-5D (European Quality of Life - 5 Dimensions Questionnaire) is a standardized instrument for use as a measure of health outcome.

It has two components:

  1. the EQ-5D descriptive system (i.e., the EQ-5D Index Score, comprised of five items), and
  2. the EQ-5D VAS. EQ-5D Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Patients reported either "problem" or "no problem" with each of the five dimensions of health. The EQ-5D VAS is a 20-cm scale with endpoints labeled "best imaginable health" and "worst imaginable health" anchored at 100 and 0, respectively.
12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)
Assessment of Long Term Use and Safety of Adalimumab as Prescribed by the Dermatologist in a Normal Clinical Setting and in Accordance With the Terms of the European Marketing Authorization
Aikaikkuna: 12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)
An adverse event (AE) was defined as any untoward medical occurrence in a participant, which did not necessarily have a causal relationship with their treatment. Any worsening of a pre-existing condition or illness was considered an adverse event.
12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

AbbVie (prior sponsor, Abbott)

Tutkijat

  • Opintojen puheenjohtaja: Athina Katsavou, MD, AbbVie Pharmaceuticals S.A.

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Hyödyllisiä linkkejä

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus

Tiistai 1. syyskuuta 2009

Ensisijainen valmistuminen (Todellinen)

Lauantai 1. syyskuuta 2012

Opintojen valmistuminen (Todellinen)

Lauantai 1. syyskuuta 2012

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 25. helmikuuta 2010

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 25. helmikuuta 2010

Ensimmäinen Lähetetty (Arvio)

Perjantai 26. helmikuuta 2010

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Arvio)

Perjantai 21. helmikuuta 2014

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Keskiviikko 19. helmikuuta 2014

Viimeksi vahvistettu

Lauantai 1. helmikuuta 2014

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • P11-984

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa